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Endocrine therapy is a recognised option in the treatment of chemo-resistant ovarian cancer. We conducted a nonrandomised phase
II evaluation of combination endocrine therapy with tamoxifen and goserelin in patients with advanced ovarian cancer that had
recurred following chemotherapy. In total, 26 patients entered the study, of which 17 had platinum-resistant disease. The median age
was 63 years and enrolled patients had received a median of three chemotherapy regimens prior to trial entry. Patients were given
oral tamoxifen 20mg twice daily on a continuous basis and subcutaneous goserelin 3.6mg once a month until disease progression.
Using the definition of endocrine response that included patients with stable disease (SD) of 6 months or greater, the overall
response rate (clinical benefit rate) was 50%. This included one complete response (CR) (3.8%), two partial responses (PR) (7.7%)
and 10 patients with SD (38.5%). The median progression-free interval (PFI) was 4 months (95% CI 2.4–9.6) while the median
overall survival (OS) was 13.6 months (95% CI 5.5–30.6). Four patients received treatment for more than 2 years (range 1–31) and
one of them is still on treatment. In none of the four patients was there any evidence of recurrent or cumulative treatment related
toxicity. Treatment-limiting toxicity was not seen in any of the study population. Endocrine data demonstrated a marked suppression
of luteinising hormone (LH) and follicle-stimulating hormone (FSH) to less than 4% of baseline values. No consistent correlation could
be established between LH/FSH suppression and tumour response. Likewise no relationship was observed between Inhibin A/B
and pro-alpha C levels and tumour response. Inhibin is unlikely to be a useful surrogate marker for response in locally advanced or
metastatic ovarian cancer. Combination endocrine therapy with tamoxifen and goserelin is an active regimen in platinum-resistant
ovarian cancer patients. Hormonal therapy is advantageous in its relative lack of toxicity, ease of administration and tolerability, thus
making it suitable for patients with heavily pretreated disease, compromised bone marrow function and other comorbid conditions
that contraindicate cytotoxic therapy as well as in patients with indolent disease.
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Ovarian cancer is the leading cause of mortality from gynaecolo-
gical malignancies in the western world (Greenlee et al, 2001).
Every year 5000 women die from this disease in the UK and 25000
in the United States. Through the administration of platinum-
paclitaxel chemotherapy after expert gynaecological surgery,
recent trials have demonstrated a median survival of 3 years in
women with advanced ovarian cancer (McGuire et al, 1996; Piccart
et al, 2000). Over 70–80% of patients present with advanced
disease (stage III/IV). The majority of these patients will develop
recurrent disease from which they will die and new treatment
strategies are needed. In particular, the management of platinum-
resistant disease poses a major problem given the limited
effectiveness of nonplatinum compounds in this setting. Patients
have depleted bone marrow reserves in the presence of heavily
pretreated disease and poor performance status that compound
the complexity of the problem.
Clinical studies of endocrine therapy in ovarian cancer
have evaluated a number of agents including antioestrogens,
oestrogens, progestogens, aromatase inhibitors and GnRH
agonists. Tamoxifen is one of the most extensively studied com-
pounds among these. The mechanism by which tamoxifen works
in ovarian cancer is not known; however, some data suggest
that the antioestrogen effect is important as other antioestrogens
inhibit ER
þ ovarian cancer cells in vitro (Langdon et al, 1994).
Several studies have shown a response rate of 10–20% with
oral tamoxifen in patients with platinum-resistant ovarian
cancer (Slotman and Rao, 1988; Hatch et al, 1991; Ahlgren et al,
1993). Two systematic reviews have reported response rates of
13 and 9.6% respectively (Williams, 2001; Perez-Garcia and
Carrasco, 2002).
Owing to the close temporal relationship between the increase in
incidence of ovarian malignancies and the rise in serum
gonadotropin concentrations, it has been suggested that gonado-
tropins are also involved in the development of ovarian tumours
(Emons and Schally, 1994; Imai et al, 1994). However, continuous
stimulation of the pituitary by chronic administration of
gonadotropin-releasing hormone (GnRH) agonists like goserelin
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sinhibits the hypothalamic–pituitary–gonadal axis by downregula-
tion of the pituitary LH-RH receptors leading to suppression of
LH and gonadal steroid production. Furthermore, treatment of
patients with LH-RH, resulting in reduced gonadotropin concen-
trations has been associated with a 17% response rate in patients
with advanced disease (Kavanagh et al, 1989).
Trials of LH-RH agonists in ovarian cancer have shown
objective response rates ranging from 6.6 to 17.4% in various
studies with response durations of the order of a few months (Lind
et al, 1992; Sevelda et al, 1992; Paskeviciute et al, 2002). Response
to goserelin was not correlated to histological grading or other
tumor parameters. No significant treatment-related toxicities were
seen in any of the above studies.
We were interested in the apparent paradox that tamoxifen has
some antitumour activity in ovarian cancer whereas hormone
replacement therapy (HRT) is deemed safe in women who have
ovarian cancer (Eeles et al, 1991). One hypothesis to explain this is
that HRT decreases the release of LH, a known mitogen for ovarian
cancer; thus, the potential growth promoting effect of HRT is offset
by the reduction in LH, which is usually high in postmenopausal
women or in women who have undergone bilateral oophorectomy.
If this is correct then the addition of goserelin to tamoxifen should
be associated with greater anticancer activity. In keeping with
these preclinical studies, an antiproliferative activity of tamoxifen
was demonstrated in ovarian cancer cell lines. GnRH analogues
have direct inhibitory effects on ovarian tumour growth that are
distinct from the indirect steroid hormone-mediated effects
(Emons et al, 1989; Connor et al, 1994; Imai et al, 1994; Grundker
et al, 2000). These data suggest that the treatment of patients with
a combined antioestrogen (tamoxifen) and an LH suppressant
(goserelin) might improve the efficacy of endocrine therapy in
ovarian cancer. This study was therefore set up as a phase II
evaluation of combination endocrine therapy with tamoxifen and
goserelin in patients with advanced ovarian cancer.
Study design
This was an open label, nonrandomised phase II study designed
to determine the response rate (CR or PR or SD of greater than 6
months duration) and progression-free interval in patients with
advanced ovarian cancer treated with tamoxifen and goserelin. In
breast cancer the survival of patients treated with tamoxifen who
had stable disease (SD) for 6 months is the same as those who
attain a partial response (Howell et al, 1988). We therefore decided
to include patients who had SD of at least 6 months in our
definition of clinical response (clinical benefit rate). The study
protocol was approved by the local research ethics committee.
Both tamoxifen (Nolvadex
s) and goserelin (Zoladex
s) were
supplied by Astra-Zeneca. All patients gave informed consent
prior to trial entry.
Inclusion criteria
Patients were eligible if they had histologically proven epithelial
ovarian cancer that had progressed during or after completion
of at least one platinum containing chemotherapy regimen,
which usually included a taxane. Patients were also required to
have adequate haematological reserves (HbX10gdl
 1, WBCX3 
10
9l
 1, PlateletsX100 10
9l
 1), renal function (serum creatinine
o120mM) and liver function (serum bilirubin o30mM, AST/ALT
o2.5 ULN in the absence of demonstrable liver metastases or
o5 ULN in the presence of liver metastases). Patients must have
had a WHO performance status of 0–2 and bidimensionally
measurable disease on X-ray, ultrasound, CT or MRI that was
equal to or greater than 2cm. Measurements must have been
made within 4 weeks of trial entry. Those who had prior endocrine
therapy for ovarian cancer were excluded, as were patients with
significant comorbidity and/or active brain metastases. Patients
were also required to stop HRT, immunotherapy or chemotherapy
4 weeks prior to trial entry.
Patient evaluation and treatment
Pretreatment evaluation consisted of a physical examination,
laboratory investigations as described above while additional
samples were taken for CA125 and hormonal analysis (LH, FSH,
inhibin A, inhibin B and pro-alpha C subunit of inhibin A).
A pretreatment staging CT scan was performed on all patients
at trial entry. Patients were reviewed at four weekly intervals
for laboratory investigations and clinical, toxicity and laboratory
assessment. Radiological evaluation was carried out every
3 months.
Patients were given oral tamoxifen 20mg bd on a continuous
basis and subcutaneous goserelin 3.6mg, once a month for 6
months. Treatment was continued beyond 6 months in patients
with stable or regressing disease until disease progression. No
patients were excluded from response analysis or toxicity
assessment. Response valuation was based on regression of
bidimensionally measurable disease on CT measurement of
tumours using WHO criteria.
Hormone assays
Plasma concentrations of LH and FSH were measured by radio
immunoassay previously described (Perheentupa et al, 2000),
with assay sensitivities of 0.8 and 0.9IUl
 1, respectively, and
within-assay variabilities of 4.6 and 5.0%, respectively. Inhibin B
(Groome et al, 1996), inhibin A (Groome et al, 1994) and Pro-alpha
C (Groome et al, 1995) concentrations were measured using
two-site ELISA as described previously. The CV were o8% within
plate and o10% between plates for each of these assays with
sensitivities of 7.8pgml
 1 for inhibin B, 2pgml
 1 for inhibin A
and 5pgml
 1 for Pro-alpha C.
Statistics
In total, 26 eligible patients were recruited to the study. The trial
was designed to be terminated if no responses were observed in the
first 14 patients. This scheme ensured that if the combination was
active in 20% or more patients, the chance of erroneously rejecting
the treatment after the first 14 patients was 0.044. Those who
showed evidence of clinical benefit were allowed to continue
treatment until disease progression, severe side effects or at
patient’s request to discontinue treatment.
Baseline characteristics
In total, 26 patients entered the study. The median age of patients
was 63 years (range 49–79). The median number of prior
chemotherapy regimens was 3 (range 1–8). In total, 17 patients
had platinum-resistant disease, defined as disease progression
within 6 months of previous platinum therapy. Nine patients with
platinum-sensitive disease opted for the study in preference to
chemotherapy. Standard first-line therapy pre-1998 was carbo-
platin and cyclophosphamide. Thereafter patients were treated with
carboplatin and paclitaxel unless taxanes were contraindicated
on medical grounds. Over 50% of the patients had poorly
differentiated tumours and multiple intra-abdominal disease sites
although only a third of patients had disease that exceeded 5cm
diameter. Serous histology was the most common (50%). All
patients had evidence of progressive disease at trial entry. A
median of four cycles of treatment was administered per patient
(range 1–31).
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sRESULTS
At the time of analysis, 19 of the 26 patients had died. The median
follow-up on the remaining seven patients was 27.6 months (range
9.6–43.2). Using the definition of endocrine response that
included patients with SD of 6 months or greater, the overall
clinical benefit rate was 50%. This included one complete response
(CR) (3.8%), two partial responses (PR) (7.7%) and 10 patients
with SD (38.5%) that persisted for at least 6 months. The median
PFI was 4 months (95% CI 2.4–9.6) (Figure 1) while the median OS
was 13.6 months (95% CI 5.5–30.6) (Figure 1). There was good
correlation between Ca125 and radiological response to treatment
in 14 out of 15 patients on whom data was available. In only one
patient, Ca125 did not match radiological response.
The treatment was well tolerated and no grade III/IV toxicities
were reported. No patient was required to discontinue treatment
on account of toxicity. The most common side effects were grade
I–II hot flushes reported in 10 patients. Grade I abnormalities in
liver enzymes were reported in two patients and weight gain in
another two. A fatty liver was noted in a single patient. One patient
had a pulmonary embolism that was considered to be disease-
related. Four patients received treatment for more than 2 years
(range 1–31). Of these three had SD and one patient had a CR. In
none of the four patients was there any evidence of recurrent or
cumulative treatment related toxicity.
Blood samples were taken for LH, FSH, Inhibin A and B and the
pro-alpha C subunit of Inhibin and endocrine data were available
on 11 patients. Of these one patient had a CR, eight had SD and two
patients progressed on treatment. There was a marked suppression of
LH and FSH to less than 4% of baseline values in the majority of
patients. There was no significant change in serum levels of inhibin A
and B post-treatment compared to pretreatment samples and all levels
remained at, or below, the detection limits of the assays. Pro-alpha C
levels fluctuated through the course of treatment, although an initial
suppression of pro-alpha C levels was noted in all 11 patients. No
consistent correlation could be established between LH/FSH suppres-
sion and tumour response. Likewise no relationship was observed
between Inhibin A/B and pro-alpha C levels and tumour response.
DISCUSSION
In the only combination therapy study to date, Hofstra et al (1999)
evaluated the efficacy of tamoxifen 20mg a day and goserelin
3.6mg each month in 25 patients with chemo-resistant disease.
In this case the progression free interval was 5 months (2–96)
and the median overall survival (OS) was 8 months (3–96). In
our study, the combination of oral tamoxifen 20mg bd and
subcutaneous goserelin 3.6mg once a month led to one CR
(3.8%), two PRs (7.7%) and 10 patients with prolonged SD
(38.5%). Interestingly, the patient with a CR had platinum-
resistant disease at trial entry (treatment-free interval o6 months)
as did seven of 10 patients who had SD for 6 months. Data on the
treatment–free interval for the two patients who experienced a
partial response were unavailable. The median PFI was only 4
months, in keeping with the short response duration observed with
other single-agent chemotherapy studies in this setting (Markman
and Bookman, 2000). The median OS was 13.6 months with a
substantial minority of patients surviving well beyond 2 years
(Figure 1). Over a third of enrolled patients had SD for at least 6
months. The response rate and response duration observed in
our study are significant given that the study group comprised
of patients with adverse prognostic indicators and cannot be
explained by selection bias or inclusion of patients with indolent
disease. Indeed, the majority of patients recruited had biologically
aggressive disease (450% had platinum-resistant disease, sig-
nificant tumour burden and poorly differentiated tumours. The
former two being recognised adverse prognostic factors in
advanced ovarian cancer). Three out of four patients who carried
on with treatment for two or more years had platinum-resistant
disease and multiple sites of disease. The majority of patients were
heavily pretreated, having received a median of three previous
chemotherapy regimens. All patients had radiological evidence of
progression at trial entry.
As all patients had progressive disease at study entry, it is
reasonable to conclude that combination endocrine therapy can
control disease in a long-term fashion with minimal toxicity.
Despite its modest efficacy, combination endocrine therapy offers
an alternative option particularly in patients with heavily
pretreated disease and limited bone marrow reserves and for
patients with poor performance status who would not tolerate
cytotoxic agents. The population recruited to this trial had
received multiple courses of chemotherapy, and it would be
interesting to evaluate the regimen in less chemo-resistant disease.
Endocrine analysis as expected showed a significant suppression
of LH and FSH levels. However, this did not correlate with clinical
response to treatment. This is in keeping with findings from recent
studies that indicate the classical LH-RH receptor signal transduc-
tion pathways known to operate in the pituitary are not involved in
mediating the antiproliferative effects of LH-RH analogues.
Instead, these agents exert their antimitogenic effect through
interference with the signal transduction of growth-factor recep-
tors and related oncogene products associated with tyrosine-kinase
activity. The mechanism of action is probably an LH-RH-induced
activation of a phosphotyrosine phosphatase, counteracting the
effects of receptor associated tyrosine kinase (Emons et al, 1998).
The antiproliferative effect of GnRH analogues is also dose-
dependent. Higher tissue concentrations achieved by escalating
dosing regimens or alternative routes of administration may yield
better responses and requires further evaluation (Emons and
Schulz, 2000).
The significance of secretion of functional inhibin by epithelial
ovarian cancers is not clear. Elevated serum inhibin levels have
been noted in postmenopausal women with ovarian tumours
(Healy et al, 1993) and it has been suggested that inhibin may have
a role as a tumour marker, particularly when used in combination
with CA125 (Robertson et al, 1999). Elevated serum inhibin and
pro-alpha C levels have been reported in patients with GCTs and
mucinous tumours of the ovary (Healy et al, 1993; Jobling et al,
1994; Boggess et al, 1997). Serum inhibin has never been evaluated
as a marker for response to treatment in epithelial ovarian cancer
although a small series has evaluated it in monitoring response to
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Figure 1 Kaplan–Meier curve for progression-free survival and overall
survival with tamoxifen and goserelin. Figures below X-axis legend indicate
patients free from progression and patients alive at six-monthly time points
from the start of the treatment.
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show that inhibin assays, which detect all inhibin forms, that is,
assays that detect the alpha subunit both as the free form and as
an alpha-beta subunit dimer, provide the highest sensitivity and
specificity for diagnosing ovarian cancer (Robertson et al, 2002).
We therefore prospectively evaluated serum inhibin (inhibin A
(alpha-betaA), inhibin B (alpha-betaB)) and pro-alpha C as
potential surrogate markers of response to endocrine therapy in
patients with advanced epithelial ovarian cancer. In our study, no
relationship was observed between serum inhibin A/B and pro-
alpha C levels and clinical response. An initial suppression of
pro-alpha C levels was noted in all patients on whom data were
available. The clinical significance of this remains unclear. It has
been suggested that elevated serum inhibin levels in epithelial
ovarian cancers are a consequence of production and secretion by
the stroma rather than epithelial tumour cells (Zheng et al, 2000).
Serum inhibin levels correlate with the extent of stroma, with
stroma in mucinous tumours and sex cord tumours being more
extensive than in other histological subtypes. Thus, while serum
inhibin may be a useful marker for epithelial ovarian tumours
confined to the ovary, it may not be appropriate in monitoring
disease or response to treatment when the tumour has meta-
stasised to other tissues.
CONCLUSION
Combination endocrine therapy with tamoxifen and goserelin is an
active regimen in platinum-resistant ovarian cancer patients.
Hormonal therapy is advantageous in its relative lack of toxicity,
ease of administration and tolerability, thus making it suitable
for patients with heavily pretreated disease, compromised
bone marrow function and other comorbid conditions that
contraindicate cytotoxic therapy as well as in patients with slowly
progressive disease. Prolonged survival was noted in some patients
and response rates were similar to those observed with other
single-agent chemotherapy, although prospective randomised
studies need to be performed to confirm the superiority of this
regimen.
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